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Objectives: To evaluate the effectiveness of Hydroxychloroquine Phosphate/Sulfate (200 mg orally 8 hourly thrice a
day for 5 days), versus oseltamivir (75 mg orally twice a day for 5 days), and versus Azithromycin (500 mg orally daily
on day 1, followed by 250 mg orally twice a day on days 2-5) alone and in combination (in all seven groups), in
clearing the coronavirus (COVID-19) nucleic acid from throat and nasal swab and in bringing about clinical
improvement on day 7 of follow-up (primary outcomes).
Trial Design: An adaptive design, set within a comprehensive cohort study, to permit flexibility in this fast-
changing clinical and public health scenario. The randomized study will be a multicenter, multiarm, multistage,
randomized controlled trial with a parallel design. An observation only cohort will emerge from those not
consenting to randomization.
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Participants: Eligible will be newly diagnosed patients, either hospitalized or in self-isolation, without any
comorbidities or with controlled chronic medical conditions like diabetes mellitus and hypertension. Participants of
any gender or age group having tested positive for COVID-19 on Real-Time qRT-PCR (Quantitative Reverse
Transcription PCR) will be invited to take part in study at twelve centers across eight cities in Pakistan. Those
pregnant or lactating, severely dyspneic or with respiratory distress, already undergoing treatment, and with serious
comorbidities like liver or kidney failure will be excluded.
Intervention and Comparator: There will be a total of seven comparator groups: Each drug (Hydroxychloroquine
Phosphate/Sulfate, Oseltamivir and Azithromycin) given as monotherapy (three groups); combinations of each of
two drugs (three groups); and a final group on triple drug regimen.
Main Outcomes: The laboratory-based primary outcome will be turning the test negative for COVID-19 on qRT-
PCR on day 7 of follow-up. The clinical primary outcome will be improvement from baseline of two points on a
seven-category ordinal scale of clinical status on day 7 of follow-up.
Randomization: Participants will be randomized, maintaining concealment of allocation sequence, using a
computer-generated random number list of variable block size into multiple intervention groups in the allocation
ratio of 1:1 for all groups.
Blinding (masking): This is an open label study, neither physician nor participants will be blinded.
Numbers to be randomized (sample size): This is an adaptive design and parameters for formal sample size
calculation in a new disease of a previously unknown virus are not available. Thus, the final sample size will be
subjected to periodic reviews at each stage of adaptive design and subsequent advice of National Data Safety &
Management Board (NDSMB) notified by Drug Regulatory Authority of Pakistan.
Trial Status: Protocol Version 1.7 dated July 5, 2020. By July 03, 2020, the trial had recruited a total of about 470
participants across 12 centers after approval from the National Bioethics Committee and Drug Regulatory Authority
of Pakistan. Recruitment started on April 20, 2020. The recruitment is expected to continue for at least three months
subject to review by the National Data Safety and Management Board (NDSMB) notified by Drug Regulatory
Authority of Pakistan.
Trial Registration: Prospectively registered on 8 April 2020 at clinicaltrials.gov ID: NCT04338698
The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in
expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of
the key elements of the full protocol.
The study protocol has been reported in accordance with the Standard Protocol Items: Recommendations for Clinical
Interventional Trials (SPIRIT) guidelines (Additional file 2).
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